FDA Forced To Update Approved Products List In Do-Not-Compound Review
ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.
You may also be interested in...
Advisory committee votes to add oxycodone to do-not-compound list, but will compounders now begin producing abuse-deterrent formulations?
In first meeting after multi-year absence, FDA’s Pharmacy Compounding Advisory Committee takes 33 votes on do-not-compound and bulk substances lists.
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.